
|Articles|December 8, 2013
Arming an Anti-CD38 Antibody With Interferon in Myeloma
Author(s)James R. Berenson, MD
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Advertisement
Clinical Pearls
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
- Interferon was used to treat myeloma (maintain remissions) in the 1980s and 1990s
- When paired with interferon, this anti-CD38 agent can enhance tumor-specific activity 10,000x compared with native interferon
- This pairing cured multiple tumors in mice
- It remains unknown if this pairing will have effects on immune and other cells in the human body
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































